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Jim Gilliam’s research interests throughout his career were forced upon better defining the relationships that exist between
the cutaneous and systemic manifestations of the rheumatic diseases. Although the majority of his time was spent studying
such relationships in lupus erythematosus patients, he was also intensely interested in dermatomyositis (DM) in this regard
as well. He was particularly intrigued with the dissociation of the cutaneous and muscular manifestations of this disorder
that occasionally occurs. The term ‘‘dermatomyositis sine myositis’’ has been used in the past to describe patients who
present with only the cutaneous manifestations of DM; however, very little published data is available from systematic
examinations of such patients. For several reasons, we have preferred the term ‘‘amyopathic dermatomyositis’’ to describe
that rare patient who for long periods of time suffers from the classical skin lesions of DM as the only clinically significant
manifestation of their disease. In this presentation, we review our own personal experience with a group of six such
patients and compare and contrast it to that of other workers who have dealt with this subject over the past two decades.
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Any stigmata will do to beat a dogma
—Phillip Guidella (1899–1944) [1]
In any other review of autoimmune connective tissue diseases, the
topic of amyopathic dermatomyositis (ADM) would probably not be
covered because it is a relatively new concept [2] as well as a rather
controversial one [3,4]. However, because this is a memorial to
Dr. James N. Gilliam, it is fitting that this subject be reviewed here
because it is one in which Dr. Gilliam was much interested and one that
he would quite likely have tackled himself had he been allowed more
time to pursue his beloved work.
The thesis of this presentation is that florid cutaneous manifestations
of dermatomyositis (DM) can occasionally be present in a patient for a
prolonged period of time (if not permanently) without any clinical
evidence of underlying inflammatory muscle disease. Although this is not
a totally new notion to dermatologists (i.e., the ill-defined concept of
‘‘dermatomyositis sine´ myositis’’), it is one that is not at all accepted by
physicians outside our specialty because the somewhat dogmatic but
widely accepted criteria for the diagnosis of polymyositis/dermatomyo-
sitis (PM/DM) formulated by Bohan and Peter in 1975 [5] do not allow for
the diagnosis of any form of DM in patients who do not have firm
evidence of myositis. It is our view that because such patients clearly
exist and because considerable confusion currently surrounds them, they
deserve further study in order to determine the most logical and efficient
means or managing their particular variety of disease.
NOMENCLATURE
While reviewing this subject after seeing a six-year-old girl with florid
cutaneous manifestations of DM but no underlying clinical or enzymatic
evidence of muscle disease for over two years, we were quite surprised to
find no references in the National Library of Medicine’s Medline
database (including backfiles through 1966) under the search term
‘‘dermatomyositis sine´ myositis.’’ However, we did find a textbook
reference to such patients made by Carl Pearson, M.D. [6], a pioneering
rheumatologist, who stated
Although the diagnosis of polymyositis rarely can be made in the
absence of muscular weakness, I have for some time observed five
women who show the completely typical erythematous heliotrope
eruption as already described in association with erythematous
plaques on the elbows and elsewhere. In none can I find any
evidence of muscle disease or any other disorder. One woman has
been observed repeatedly for thirteen years. Hence, it may be
possible to disassociate the dermal from the muscular component
in rare instances, whereas in many cases a myositic process
occurs without any dermal features. In six other persons (four
women and two men), the rash was florid whereas weakness and
EMG changes were minimal. This variant could be called
amyopathic dermatomyositis.
Hence, in honor of Dr. Pearson for recognizing these patients and for his
many other contributions to our current understanding of PM/DM in
general, we felt that it would be appropriate to use his term ‘‘amyopathic
dermatomyositis’’ for patients in whom the cutaneous manifestations of
DM was the sole clinical manifestation of their disease for prolonged
periods of time.
PRIOR OBSERVATIONS BY OTHERS
Dr. Lawrence Krain [7] was the first investigator to formally evaluate the
issue of DM without muscle involvement in the modern English medical
literature. He described six patients with skin changes of DM and no
muscle involvement initially, all of whom later developed myositis. The
first case described a 10-year-old girl who had skin disease that preceded
muscle weakness by four months. Case 2 concerned a man with
cutaneous disease preceding muscle disease by six years. Cases 3 and 4
were two women who had skin disease that preceded muscle disease by
five years. Case 5 had concurrent skin changes with mild shoulder
weakness. His skin lesions progressed and the weakness became
clinically significant after six years. This patient also had associated
pulmonary fibrosis. Case 6 was a 72-year-old woman who presented
initially with concurrent muscle disease and skin disease, both of which
resolved spontaneously. Four years later, her skin changes recurred
without muscle disease. Six years after that, her muscle disease recurred.
This patient also developed pulmonary fibrosis. Krain pointed out that
‘‘the failure to recognize dermatomyositis in the absence of detectable
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muscle weakness, despite a characteristic skin eruption, resulted in a
considerable delay in diagnosis.’’ He also concluded that the resistance
of the cutaneous findings to corticosteroid therapy generally indicated a
poorer prognosis.
The same year that Krain’s article was published (1975), Bohan and
Peter [5] published their landmark article in which criteria were
presented that must be met in order to make a diagnosis of PM/DM
(symmetrical proximal muscle weakness with or without dysphagia or
respiratory muscle involvement, abnormal muscle biopsy, elevation of
skeletal muscle-derived enzymes, abnormal electromyo-gram, typical
skin rash; confidence limits for diagnosis of definite DM are rash and
three or four other criteria, for probable DM are rash and 2 other criteria,
and for possible DM are rash and one other criteria [5]). As a result of this
article as well as their later work [8], almost every published report of
DM patients since 1975 has used these criteria to select patients for
review. Because these criteria employ muscle disease as the sine´ qua non
for the diagnosis of DM, patients who have DM skin disease but lack
muscle disease have been excluded from these reviews. Hence, there has
been a bias towards not reporting ADM patients that has resulted in a
dearth of information in the modern literature on this subject. What
follows is a chronologic review of the data concerning ADM that has
appeared since the Bohan and Peter criteria were presented in 1975.
In 1977, Bohan et al [8] used their published criteria to select patients
for a study entitled ‘‘A Computer Assisted Analysis of 153 Patients with
Polymyositis and Dermatomyositis.’’ In this article, they described three
patients (2%) who ‘‘failed to develop evidence of significant muscle
weakness while clearly meeting other diagnostic criteria.’’ They also
stated that muscle strength was normal in 48 patients (31%) upon initial
presentation. Unfortunately, they did not specify the length of time
between skin disease presentation and onset of muscle disease in this
subgroup of patients. Several other groups of workers have suggested that
this interval is usually less than 2 years and often less than six months
[9–13].
Fernandes et al [14] in 1979 described a 48-year-old West Indian
patient who had DM skin disease and pulmonary disease but no muscle
disease who died of his fibrosing alveolitis just ten months after coming
under observation.
In 1981, Braverman [15] described a 13-year-old caucasoid female
with classic cutaneous changes of DM without muscle disease for 10
years and a 16-year-old female with characteristic DM skin lesions
without evidence of myositis. In this last patient, oral and topical
corticosteroids provided no relief and the skin eruption disappeared
spontaneously after 2 years. He also described another patient who had
only the cutaneous findings of DM as a manifestation of underlying lung
cancer.
Three years later, Woo et al [16] reported seven patients with DM
whose skin lesions had not responded to oral corticosteroids but did
improve with the addition of hydroxychloroquine. One of these patients
did not have myositis. In 1985, Taieb et al [17] reviewed their experience
with childhood DM and found eight individuals in their review of 70
cases whom they retained in their study as possible DM patients—
patients who had the typical cutaneous changes of DM without clinical
or laboratory evidence of muscle involvement at the time of their initial
evaluation.
Gertner and Urowitz [18] also reported in 1985 a 24-year-old woman
who initially presented with concordance of muscle and skin involve-
ment. She was treated with prednisone with resolution of the myositic
component of her disease with persistence of the cutaneous component
for 17 years before once again developing myositis.
Caro [19], in 1988, alluded to following a patient for several years
who had all the typical skin findings of DM but no clinical or enzymatic
evidence of muscle disease.
Rockerbie et al [20] in an article entitled ‘‘Cutaneous Changes of
Dermatomyositis Precede Muscle Weakness’’ retrospectively reviewed
50 patients with DM. All patients included in this analysis met at least
four or more of the five Bohan and Peter criteria and were thus classified
as having at least definite DM by that classification scheme. The onset of
skin lesions in these patients ranged from 51 months before to 14 months
after the onset of muscle weakness. In those patients whose skin disease
preceded muscle disease (56% of the entire group), the mean interval
(± one standard deviation) between onset of cutaneous changes and
muscle weakness was 4 (±11 months). Four patients (12%) had
cutaneous changes greater than 1.75 years before onset of muscle
weakness. Interestingly, although not statistically significant, the mean
skin/muscle discordance for the female group of patients was 5 months
(±12 months) compared with 1 (± 8 months) for the male group. These
workers also examined the relationship between skin and muscle
discordance and patient outcome. Of the four deaths during the
follow-up period, none of the patients had a history of skin/muscle
discordance greater than 3 months. There was only one documented
malignancy in this series, occurring in a patient with no history of
skin/muscie discordance. Of their 50 patients, 41 (82%) were less than
25 years old. In this younger subgroup, the mean skin/muscle discor-
dance was 4 months compared to a mean skin/muscle discordance of
8 months in the 9 patients over 25 years of age.
OBSERVATIONS ON OUR OWN PATIENTS
In our own study [2], we reviewed six patients with the classic cutaneous
findings of DM who did not develop clinical or laboratory evidence of
muscle disease for at least 2 years following the onset of their skin
disease. The decision to use 2 years as a cut-off time was an arbitrary one
based on the experience of other investigators, suggesting that most
patients with classical DM usually develop muscle disease within two
years after onset of their skin disease [9–13,20].
Unlike previous studies, the criteria set forth by Bohan and Peter [5]
were not used as inclusion criteria for our study. To the contrary, if those
criteria had been used, these patients would not have been included as
they did not meet the requirements for the diagnosis of definite DM. Even
if an electromyogram (EMG) and muscle biopsy had been performed and
had been positive, our patients would have only met the criteria for
probable or possible DM because they lacked proximal muscle weakness
and elevated muscle enzymes. We did not believe these procedures were
clinically indicated because the results either positive or negative would
not have influenced our treatment approach. All five of our adult ADM
patients had failed conservative topical treatment and all had long-
standing, disabling cutaneous symptoms severe enough in our opinion to
warrant a trial of more aggressive systemic medical management. When
one sees a patient with the unequivocally classical cutaneous changes of
DM with no muscle weakness by history or exam and normal skeletal
muscle enzymes, we have found that it is often difficult to convince that
patient to undergo a muscle biopsy (not a trivial procedure either
medically or economically), when this information is quite unlikely to
change what one is going to recommend concerning treatment.
Patients were included in our review only if they met all four of the
following criteria that we are here proposing for the diagnosis of ADM:
1) presence of pathognomonic clinical changes of cutaneous DM (to be
considered for the diagnosis of ADM, each patient had to have fully
established or incipient Gottron’s papules, periungual nailfold erythema/
telangiectasia, and violaceous erythema/edema of the face including a
periorbital distribution), 2) a skin biopsy specimen compatible with DM,
3) no clinical evidence of proximal motor weakness in the shoulders or
hips within 2 years of skin disease onset, and 4) normal skeletal muscle
enzyme levels (creatine kinase [CK] and aldolase) within the first 2 years of
their illness. Six of the fifty DM patients (11%) seen by one of the authors
(RDS) in our department during the past 15 years met these criteria. This
prevalence rate is similar to that of the four patients with skin/muscle
discordance of 1.75 years or greater reported in the study by Rockerbie
et al [20]. However, since all of their patients ultimately met criteria for
definite DM, all of their patients ultimately developed muscle disease.
At the time of publication, our patients had skin disease for a mean
duration of 3.8 years (range 2–8 years). The pediatric patient began to
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complain of intermittent muscle pain in her proximal thighs after 3 years
of skin disease. Physical exam revealed normal muscle strength but an
EMG was abnormal although her muscle enzymes remained normal. Of
the adult patients, one has been followed for four years, two for five
years, and one each for seven and ten years respectively with no muscle
disease.
All five of the adult patients in our series were treated initially by us
with moderate to high-dose prednisone (40–60mg/d) for their increas-
ingly symptomatic skin disease. These patients had skin disease resistant
to topical therapy (including corticosteroids and sunscreens) for a mean
duration of 14 months prior to seeing us. All patients began to respond
within 4–6 weeks of treatment, at which point tapering of the prednisone
was begun and adjusted on the basis of clinical response. One year after
starting prednisone, all five patients had none-to-minimal skin disease
and were taking no more than one-half their original dose of prednisone
daily. This slow rate of corticosteroid taper is generally required in DM to
prevent recrudescence of disease activity. Hydroxychloroquine was
added as a steroid-sparing agent in three patients. One patient had to
discontinue this drug because of a cutaneous hypersensitivity reaction.
One of the oldest patients in our series did develop a minimal degree of
glucose intolerance while on corticosteroids. None of the other patients
had significant side effects from corticosteroids.
COMPARISON OF OUR EXPERIENCE
TO THAT OF OTHERS
Similarities between the patients described in the Rockerbie et al study
[20] and our own [2] included a greater female-to-male ratio (3:1) than
has been reported in other DM patient series (i.e., 2:1) [8]. In addition,
underlying malignancies did not occur in patients described by Rock-
erbie et al whose skin disease preceded their muscle disease nor were
malignancies present in our six patients (subsequent to the publication of
our report we have seen an additional female ADM patient who
developed ductal carcinoma of the breast approximately two and one-
half years following the onset of her skin disease [4]). We have also
recently been made aware of several other cases of ADM that have been
associated with internal malignancy (Dr. T.T. Provost, personal commu-
nication, August, 1991). Interestingly, it appeared that although the
majority of the DM patients in the Rockerbie study were less than 25
years of age, those with the greatest discordance between the onset of
skin and muscle disease were older than 25. Among our six patients,
there was one six-year-old pediatric patient. The average age of the
remaining five patients was 53.6 years old. The mean time in months
between onset of skin disease and presentation to our department in our
series of patients was 14 months (range 5–24 months). In Krain’s study, it
was 18 months (range, 2–50 months).
The most common erroneous initial diagnoses given our patients
before seeing us were 1) lupus erythematosus, 2) contact dermatitis, 3)
lichen planus, 4) psoriasis, and 5) seborrheic dermatitis. Other erroneous
initial diagnoses reported in Krain’s study were polymorphous light
eruption, atopic dermatitis, and erythroderma. All patients in our series
had moderate-to-severe pruritus, which can help distinguish DM patients
from patients with cutaneous lupus erythematosus who generally do not
complain of severe itching. All six of our ADM patients also complained
of photosensitivity.
All of our patients responded to systemic corticosteroids. This is
somewhat different from the experience of other observers who have noted
that DM skin lesions can at times be quite refractory to systemic
corticosteroid therapy [16]. We too have seen patients with classical DM
whose skin disease has been refractory to high-dose corticosteroids.
Perhaps our good fortune with our ADM patients in this regard was due
only to the small number of patients we studied or, perhaps, concurrent
muscle weakness in some way increases the likelihood of therapeutically
refractory skin disease. None of the corticosteroid-treated patients in our
series developed muscle disease as did all of Krain’s patients and,
presumably, Rock-erbie’s patients as well. A comparison of our series with
Krain’s, although admittedly not the ideal control group, suggests that our
more aggressive approach to treating the skin disease might have prevented
the development of myositis in our patients. We, however, do not have firm
data at this time to support this view. Furthermore, early treatment with
systemic corticosteroids potentially could allow lower doses and shorter
courses to be used to control the disease, thereby resulting in fewer side
effects. It should be emphasized that we only treated patients with ADM for
severely symptomatic skin disease in whom the benefits appeared to
outweigh the risks. We believed the risks of corticosteroids in our pediatric
patient with ADM were not justified and, hence, this patient was treated
more conservatively with antimalarials alone without benefit. Interestingly,
the more conservatively treated pediatric patient was the only one to
ultimately develop signs and symptoms of muscle disease.
A SURVEY OF OTHER DERMATOLOGISTS
While analyzing the results of our study, we were intrigued to know how
other practicing dermatologists dealt with patients such as ours. Therefore,
in 1988 we designed a questionnaire addressing several issues concerning
ADM and mailed it along with a standardized case report form to all 90
members of the Dallas Dermato-logical Society as well as to a total of 29
other dermatologists around the country whom, because of their clinical
interests, we felt might have seen such patients. Unfortunately, the
response to this preliminary polling was somewhat disappointing.
Although a number of individuals reported having seen such patients,
only five case report forms of patients meeting our criteria were returned
(three cases from a single local dermatologist, one case from another local
dermatologist, and a single case from a dermatologist practicing in another
part of the country). The clinical features of these five additional cases of
ADM were quite similar to those of our six patients [2]. There were mixed
opinions among the three physicians who formally responded to our
questionnaire regarding the need for EMG and muscle biopsies in such
patients as well as the justification for the type of aggressive systemic
therapy with corticosteroids that was used in our five adult patients.
ISSUES THAT DESERVE FURTHER ATTENTION
Although ADM patients are admittedly rare, they do exist and it is important
that their condition be recognized in order to identify differences that might
distinguish their form of disease from that of more classical DM patients.
For example, what is the diagnostic yield and incremental clinical benefit of
EMG and muscle biopsies in ADM patients who have no clinical or
enzymatic evidence of muscle disease? Can predictive factors be identified
in those ADM patients who are destined to develop muscle disease? Is there
a significant association between ADM and internal malignancy, and if so
what features correlate with tumor development in such patients? What is
the optimal treatment approach for ADM patients? What percentage of
ADM patients managed conservatively never develop muscle disease?
Does early aggressive treatment of skin disease significantly alter the risk for
eventually developing muscle disease? Because of the rarity of this
condition, only an appropriately designed, multicenter study will be able
to answer these questions effectively.
At the very least, ADM patients need to be recognized in order that
they can be followed more closely for the development of muscle disease
so that appropriate treatment can be instituted during the earliest phases
of this complication. In addition it is our opinion that such patients need
to be monitored for the development of internal malignancy.
SUMMARY AND CONCLUSIONS
If patients with ADM, DM, and PM are grouped together, this disease can
be viewed as a spectrum or continuum much like lupus erythematosus
with primary involvement of the skin at one extreme (ADM) and primary
muscle involvement at the other (PM) with the combination of skin
and muscle disease (more typical DM) somewhere in the middle
(Fig 1). Currently, the majority of patients who express the cutaneous
manifestations of DM appear to fall within the mid part of this spectrum.
Perhaps with earlier, aggressive treatment of patients during the
amyopathic phase of their illness, there might be a decrease in patients
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who go on to develop significant muscle involvement. We have
previously suggested [2] that the diagnostic criteria set forth for DM by
Bohan and Peter be altered to include a sixth diagnostic category,
amyopathic dermatomyositis, that would allow the diagnosis of ADM to
be made on the basis of fully-expressed, histopathologically-compatible,
classical cutaneous findings alone. The recently defined condition of
inclusion body myositis [21,22] should also be included in any such
reclassifi-cation. The types and designations we propose are I,
polymyositis; II, dermatomyositis; III, myositis with malignancy; IV,
childhood myositis; V, myositis with other autoimmune connective tissue
disorders (i.e., overlap syndromes); VI, amyopathic dermatomyositis; and
VII, inclusion body myositis.
Taking a broader view, perhaps the diagnosis of ADM need not be
limited to patients who have only skin disease for 2 years; rather, any
patient with classical DM skin disease having only equivocal evidence of
muscle disease at presentation might also warrant this designation as a
provisional diagnosis. This approach would logically lead to the division
of ADM into two subtypes—confirmed ADM representing pure ADM
patients who have only skin disease for at least 2 years, and provisional
ADM representing patients with classical skin disease who have
subjective myalgia and/or subjective weakness but no laboratory
evidence of muscle disease, patients with suggestive but not classical
skin disease (i.e., poikiloderma atrophicans vasculare, violacelous
erythema over the extensor aspects of the arms), or patients with no
clinical signs or symptoms of muscle disease but who have abnormal
laboratory tests indicative of myositis at some time during their course.
Provisional ADM patients would obviously deserve stronger considera-
tion for EMG and/or muscle biopsy to discern the basis of their symptoms
and laboratory abnormalities. The unifying feature among both subtypes
of ADM would be the presence of prominent skin disease and relative
lack of clinical muscle disease.
There are few dermatologic entities that are as clinically distinctive
and recognizable as are the fully expressed skin changes of DM. As
dermatologists we are trained to trust, beyond all others, our eyes. Let us
not be confused or apologetic for what our eyes are telling us when
confronted with patients whose only clinical problem is the presence of
the classical cutaneous manifestations of this disorder.
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Figure 1. Spectrum of clinical disease in polymyositis/dermatomyositis. The
term ‘‘amyopathic dermatomyositis’’ is used here to designate those patients
who for at least 2 years express only the classical cutaneous manifestations of
this disorder.
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